Palonosetron Fresenius Kabi

Palonosetron, the active ingredient in Palonosetron Fresenius Kabi, is a 5-HT3 receptor antagonist presented as a strength/form for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and surgery in adult patients. GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist indicated for the prevention of chemotherapy‑induced and postoperative nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the incidence of acute and delayed nausea and vomiting following highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the frequency and severity of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: provides prophylaxis against nausea and vomiting associated with radiation treatment.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Constipation - Fatigue - Diarrhoea - Dizziness

Serious or Rare Side Effects: - QT interval prolongation - Severe hypersensitivity reactions (anaphylaxis, angio‑edema) - Serotonin syndrome (when combined with other serotonergic agents) - Cardiac arrhythmias - Severe hypotension

When using Palonosetron, clinicians should consider several safety aspects.

- Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte abnormalities. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome when used with other serotonergic agents. - Pregnancy: avoid use unless clearly needed; discuss potential risks with the patient. - Breastfeeding: weigh benefits against potential infant exposure through milk. - Renal or hepatic impairment: adjust monitoring as needed for patients with severe organ dysfunction. - Store at room temperature: keep in the original packaging, protect from light and moisture.

Palonosetron may interact with other medications, requiring attention to the interaction severity.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: concurrent use can increase the risk of cardiac conduction abnormalities. - QT‑prolonging drugs: co‑administration may exacerbate QT interval prolongation.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs, triptans): monitor for signs of serotonin syndrome. - CYP3A4 inhibitors/inducers: may alter plasma levels of Palonosetron, requiring clinical observation. - Anticholinergic medications: can mask constipation, a common side effect. - Diuretics: monitor electrolytes to reduce risk of cardiac effects. - Anesthetic agents: observe for additive effects on blood pressure and heart rate.